STARTUP PROFILE

Science Corp

COUNTRY
USA
FOUNDED
2021
CATEGORY
Brain-Computer Interface
Developing optogenetic visual prostheses that use microLED arrays to restore sight by stimulating retinal neurons with patterned light.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

Science Corp

news and updates

  • 5 Oct 2026: Science reported 36-month results from the PRIMAvera trial at EURETINA. Patients gained a mean 29 letters on the ETDRS eye chart, about six lines, and 14 of 18 evaluable patients gained at least 15 letters. No new safety signal appeared after month 12, and natural vision stayed stable.
  • 22 Jul 2026: PRIMA received a CE mark for vision loss from geographic atrophy in age-related macular degeneration. The commercial launch starts in Germany, and FDA approval is pending. Read our deep dive.
  • 6 Mar 2026: Science raised a $230M Series C at a reported valuation of about $1.5B. Investors include Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT and Quiet Capital, bringing total funding to about $490M. Read our coverage.
•
Neurofounders Insights
$   Funding   -
Series C+
MODALITY
Visual prosthesis
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Vision
TARGET USER
Patients
REGULATORY STAGE
CE-Marked
Science Corp is one of the more serious visual prosthesis companies, using optogenetics and microLED arrays to stimulate retinal circuits with high precision. Its technical ambition is substantial, and it sits closer to advanced translational neuroengineering than to conventional medtech.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
11
BCI reaches a new scale
30 September – 13 October 2026

Science reported 36-month results from its PRIMA retinal implant trial in geographic atrophy. Among 18 patients assessed for efficacy, visual acuity improved by an average of 29 ETDRS letters, up from 24.5 at twelve months. 78% of patients gained at least 15 letters on the test. No new safety signals emerged after the first year. The data remain unpublished, following PRIMA's European commercial launch in July.

#
6
BCI Goes Commercial
21 July – 4 August 2026

Science received a CE Mark for its PRIMA retinal implant, launching it commercially across Europe. The 2mm photovoltaic chip sits beneath the retina and pairs with camera-equipped glasses that beam near-infrared light to power it, activating the retina directly when rods and cones have been lost. In trials, 80% of patients with advanced macular degeneration regained the ability to read letters, numbers, and words. Led by former Neuralink president Max Hodak, Science expects its first commercial implant in Germany.

Articles featuring
Science Corp